The Senate Health, Education, Labor and Pensions Committee voted to approve legislation that would reauthorize the Food and Drug Administration's drug and device user-fee programs.
The Food and Drug Administration Safety and Innovation Act would also authorize new user-fee programs for the biosimilar and generic drug industries.
User-fee programs provide funding to the FDA in exchange for performance goals. The current user-fee programs are set to expire Sept. 30 unless Congress reauthorizes them.
Sen. Tom Harkin (D-Iowa) said during today's meeting that the the legislation is expected to go to the Senate floor next month. The House Subcommittee on Health has scheduled a “markup” on legislation to reauthorize the same user-fee programs for May 8.